Navigation Links
Extended Antiviral May Benefit Kidney Transplant Patients
Date:9/17/2009

Risk of viral infection can be cut in half with 6 months of treatment, study finds

THURSDAY, Sept. 17 (HealthDay News) -- A longer period of preventive treatment after kidney transplant can help reduce the risk that the patient will become infected with a virus that can cause devastating problems, new research suggests.

Healthy people can usually fight off the virus, called cytomegalovirus, but those with kidney transplants have weakened immune systems and are more susceptible to infection, the authors of the study noted in a news release from the American Society of Nephrology.

In the comparison study, Dr. Fu Luan, of the University of Michigan in Ann Arbor, and colleagues gave kidney transplant patients either three months or six months of treatment with the antiviral drug valganciclovir. They found that those who were given the longer treatment had a rate of infection that was half that of those who received treatment for three months (12 percent vs. 24 percent).

When the researchers took into account other factors that could have played a role, they found that the longer treatment regimen lowered the risk of cytomegalovirus by nearly two-thirds.

The study also found that the longer treatment is cost-effective, although it is expensive. But the study authors contend that it's cheaper in the long run to prevent infections that could end up being very costly.

The findings appear online Sept. 17 in the Journal of the American Society of Nephrology.

More information

Learn more about kidney transplants from the U.S. National Library of Medicine.



-- Randy Dotinga



SOURCE: American Society of Nephrology, news release, Sept. 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product
2. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
3. Deadline Extended for Nominations for Jay and Rose Phillips Awards and Phillips Caregiver Award
4. Shires INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
5. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
6. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
7. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
8. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
9. Cipher receives tentative FDA approval for extended-release tramadol capsules
10. Bioniche Warrants Expiration Date to be Extended
11. Teaching Hospitals Post-Op Gains Not Extended to Blacks
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Extended Antiviral May Benefit Kidney Transplant Patients
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Cornerstone ... company, today presented data from two Phase I ... sessions at the 58th annual meeting of the ... San Diego, California . The two datasets ... with acute myeloid leukemia (AML) and T-cell non-Hodgkin,s ...
(Date:12/5/2016)... 5, 2016  Pennsylvania Physician General Dr. Rachel ... Gary Tennis today filled prescriptions for naloxone, ... in York to demonstrate how ... Levine as a prescription to acquire naloxone at any ... to remember that any Pennsylvanian can walk up to ...
Breaking Medicine Technology: